Posted from: Monday, October 31, 2016 - 03:44 PM - Present

New Dose Form for Lucentis

October 14, 2016 - The U.S. FDA approved Lucentis® (ranibizumab injection), manufactured by Gentech. Lucentis is a monoclonal antibody that is injected into the vitreous humor (jellylike filling of the eyeballs) once a month by ophthalmologists who are specifically trained in its use. It is indicated to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema caused by retinal vein occlusion (RVO). By blocking receptors for vascular endothelial growth factor (VEGF), it lessens new blood vessel formation and helps to keep blood from seeping out of leaky vessels. Pre-filled syringes each containing 0.5mg simplify the injection procedure by eliminating the need to draw the medication from a vial. 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Wednesday, July 26, 2017 - 10:56 PM.